PLPhilipp Von Landenberg

Philipp Von Landenberg

*This is an algorithmically generated author record based on publicly available information.

Philipp Von Landenberg has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • In Vitro Effects of Antiphospholipid Syndrome‐IgG Fractions and Human Monoclonal Antiphospholipid IgG Antibody on Human Umbilical Vein Endothelial Cells and Monocytes

    by Natascha Clemens, Katrin Frauenknecht, Aviva Katzav, Clemens Sommer, Philipp Von Landenberg

    It has been shown that stimulation of endothelial cells and monocytes by antiphospholipid antibodies leads to a prothrombotic state involving upregulation of tissue factor (TF). We examined the in vitro effects of IgG fractions from patients with antiphospholipid syndrome (APS) and of a β‐2‐glycoprotein 1‐independent human monoclonal antiphospholipid antibody (HL‐5B) on human umbilical vein endothelial cells (HUVEC) in comparison to untreated cell controls and to exposure to monoclonal IgG control antibody. We also examined the effect of recombinant monocyte chemoattractant protein‐1 (MCP‐1) on peripheral blood monocytes. Stimulation of endothelial cells with APS IgG fractions or HL‐5B resulted in time‐dependent upregulation of MCP‐1 mRNA and protein expression. Stimulation with HL‐5B also led to time‐dependent upregulation of interleukin (IL)‐8 and intracellular adhesion molecule‐1 (ICAM‐1) mRNA and IL‐8 protein expressions. Stimulation of monocytes with recombinant MCP‐1 resulted in an upregulation of TF mRNA and TF protein. In conclusion these results might represent a mechanism for antiphospholipid antibody‐mediated thrombosis in APS patients.


    • 1 January 2008
      • Vol. 54, 1-8

    Are porcine and human TSH receptor antibody measurements comparable?

    by Klaus Zöphel, Philipp Von Landenberg, Dirk Roggenbuck, Gerd Wunderlich, Joerg Kotzerke, Karl J Lackner

    The human TSH receptor antibody (TRAb) assay is reported to show higher sensitivity in comparison to the "classical" porcine TRAb testing. This claim is based on studies comparing porcine TSH receptor (TSH-R) in one type of assay system (non-immobilized TSH-R and PEG to separate bound and free) with recombinant human TSH-R in another type of assay system (TSH-R immobilized on plastic tubes). In this study isotopic TRAb assays both based on the "coated tube" system (second generation) were compared for the first time. Three hundred and nineteen consecutive undiagnosed patients from Mainz University as well as 72 patients from Dresden University with known Graves' disease were tested in the human TRAb assay and in the porcine TRAb assay. Spearman's coefficient of rank correlation and Chi-square test statistical analysis was performed. In the 319 consecutive patients 35 patients (11.0%) were found positive in the human assay and 36 patients (11.3%) were positive in the porcine assay. Seventy patients with Graves' disease from Dresden were positive in the assay using the porcine TSH-R and 71 out of 72 patients showed positive results in the assay with the recombinant human TSH-R. The Spearman's coefficient of rank correlation for both patient cohorts was r = 0.932 and r = 0.891 (p < 0.001), respectively. There was no significant difference in the clinical assessment regarding the diagnosis of Graves' disease. There is no clinically relevant difference in isotopic TRAb second generation assays--independent of the TSH-R used. Both TSH-R assays showed nearly similar TRAb results in consecutive samples as well as in serum samples from patients with Graves' disease.


  • Are Antiphospholipid Antibodies an Essential Requirement for an Effective Immune Response to Infections?

    by Philipp Von Landenberg, Yvonne Döring, Susanne Modrow, Karl J. Lackner

    Antiphospholipid antibodies show a close association to a variety of infections. Recent data implicate that parvovirus B19 may be used as a model‐system for studying the interaction of viral infection and the development of these autoantibodies. B19‐related diseases commonly associated with the acute infection show flu‐like symptoms, transient arthralgias, leukopenia and thrombocytopenia, and, in pregnant women, spontaneous abortion and hydrops fetalis. Hepatitis, myocarditis, meningitis, encephalitis, as well as pure red cell anemia may occur occasionally. In addition, parvovirus B19 infections have been frequently described as the cause or trigger of various forms of autoimmune diseases affecting all blood cell lines, joints, connective tissue, uvea, and large and small vessels. Molecular mimicry may be one major contribution to the appearance of autoimmune antibodies, for example, antiphospholipid and antineutrophil cytoplasmic antibodies as well as antinuclear antigens. These mechanisms implicated in the pathogenesis of parvovirus B19‐triggered autoimmune diseases, especially focused on the development of antiphospholipid antibodies, will be discussed in this mini review.


  • Human parvovirus B19 infection and antiphospholipid antibodies

    by Philipp von Landenberg, Hartwig W. Lehmann, Susanne Modrow


  • Clinical Relevance of Antiphospholipid Antibodies in Primary Biliary Cirrhosis

    by Philipp Landenberg, Michael Baumgartner, Juergen Schoelmerich, Karl J. Lackner, Reinhild Klein

    Primary biliary cirrhosis (PBC) is a cholestatic liver disease characterized by the presence of antimitochondrial autoantibodies (AMAs), but also with reactivities to other autoantigens. Recent studies showed that antibodies to phospholipids (APAs) represent an important group of autoantibodies identified in patients with PBC. In this study different types of APAs were identified in the sera of patients with PBC and autoimmune hepatitis (AIH) and control subjects. Sera from patients with PBC and AIH were tested for the presence of antibodies directed against cardiolipin (CL), phosphatidylserine (PS), and to β2‐glycoprotein I (β2‐GPI). Furthermore, an in‐house test for antithromboplastin antibodies was performed. Antinuclear antibodies (ANAs) and antimitochondrial antibodies (AMAs) were tested with standard tests. IgM anti‐PS antibodies were found in 75% of the 51 PBC patients, but only in 4% of the 48 AIH patients (P < 0.0001). IgM anti‐CL antibodies were more frequently detected in AIH than in PBC (75% vs. 89%; P= 0.045). IgM anti‐β2‐GPI antibodies were observed more frequently in patients with AIH (83%) than with PBC (59%; P= 0.007). The APAs of the IgG type did not differ significantly between the groups of patients. Considering the clinical/laboratory parameters, the levels of alkaline phosphatase (P= 0.017), glutamate pyruvate transaminase (P= 0.035), and glutamate oxalacetate transaminase (P= 0.034) were significantly higher in PBC patients who were positive for IgM anti‐PS antibodies than in the anti‐PS antibody‐negative patients. In conclusion, APAs are present in PBC patients with a higher level of the disease or more intense liver damage than in patients without APAs. Thus IgM anti‐PS antibodies represent a new marker of activity in PBC patients.


  • Neue immundiagnostische Option bei der Rheumatoid-Arthritis

    by P. von Landenberg, K. Conrad, U. Sack

    • 1 July 2004
      • Vol. 31  (7) , 1344-8

    Features associated with epilepsy in the antiphospholipid syndrome.

    by Yehuda Shoenfeld, Shaul Lev, Ilan Blatt, Miri Blank, Joseph Font, Philipp Von Landenberg, Nirit Lev, Joseph Zaech, Ricard Cervera, Jean-Charles Piette, et al.

    To assess the frequency of epilepsy in primary and secondary antiphospholipid syndrome (APS); to analyze the clinical and laboratory features characterizing those with epilepsy in a cohort of 538 patients with APS; and to find associated features that would suggest risk factors for epilepsy in APS. We analyzed the clinical features of patients with APS who had epilepsy and compared them to the clinical features of non-epileptic APS patients. Of 538 APS patients, 46 (8.6%) had epilepsy. Epilepsy was more prevalent among APS secondary to systemic lupus erythematosus (SLE) compared to primary APS (13.7% vs 6%; p < 0.05). The patients with epilepsy had a higher prevalence of central nervous system (CNS) manifestations including focal ischemic events (strokes or transient ischemic events, 54.3% vs 24.6%; p < 0.0001) and amaurosis fugax (15.2% vs 4.9%; p < 0.05). APS patients with epilepsy had a higher frequency of valvular pathology (30.4% vs 14.6%; p < 0.01), thrombocytopenia (43.5% vs 25%; p < 0.05), and livedo reticularis (26.1% vs 11.5%; p < 0.01). The multivariate logistic regression analysis found CNS thromboembolic events as the most significant factor associated with epilepsy, with an odds ratio (OR) of 4.05 (95% confidence interval, CI: 2.05-8), followed by SLE (OR 1.4, 95% CI 1.2-4.7), and valvular vegetations (OR 2.87, 95% CI 1-8.27). Epilepsy is common in APS and most of the risk seems to be linked to vascular disease as manifested by extensive CNS involvement, valvulopathy, and livedo reticularis and to the presence of SLE. These factors, however, explain only part of the increased occurrence of epilepsy in APS and other causes such as direct immune interaction in the brain should be investigated.